Impact of PSMA PET on Prostate Cancer Management

By sjmartinez • January 26, 2024

Weiner AB, Agrawal R, Valle LF, Sonni I, Kishan AU, Rettig MB, Raman SS, Calais J, Boutros PC, Reiter RE. Impact of PSMA PET on Prostate Cancer Management. Curr Treat Options Oncol. 2024 Jan 25. doi: 10.1007/s11864-024-01181-9. Epub ahead of print. PMID: 38270802.

Tags: Clinical decision-making, drug therapy, Hematology/Oncology, Neoplasm staging, Positron-emission tomography, prognosis, Prostatic neoplasms, Publications, Radiotherapy, Surgery, Theranostic nanomedicine, Veterans Administration

Related Posts

ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma

Galanina N, Iqbal M, Tomassetti S, Nousome D, Tin A, Gillespie CP, Youngberg H, Miller P, Malhotra M, Widden H, Rodriguez A, Liu MC, Narkhede[...]

Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1)

Wise-Draper TM, Robert C, Wong MK, Middleton MR, Sacco JJ, In GK, Muñoz Couselo E, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Milhem MM,[...]

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma

Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, Ascierto PA, Nathan P, Rutkowski P, Leonov OV, Lorigan P, Prey S, Saponara[...]